Ventyx Biosciences Target of Unusually High Options Trading (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors purchased 4,572 call options on the company. This is an increase of approximately 725% compared to the typical daily volume of 554 call options.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock traded up $0.07 during trading hours on Friday, reaching $2.56. The stock had a trading volume of 844,117 shares, compared to its average volume of 1,356,774. The stock has a market cap of $182.17 million, a PE ratio of -1.08 and a beta of 0.85. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $3.39. The company has a fifty day simple moving average of $1.51 and a 200-day simple moving average of $1.75.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. Research analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ventyx Biosciences

Several hedge funds have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC purchased a new position in Ventyx Biosciences in the first quarter worth about $28,000. AXQ Capital LP bought a new stake in Ventyx Biosciences during the fourth quarter valued at approximately $29,000. Palumbo Wealth Management LLC boosted its position in shares of Ventyx Biosciences by 97.1% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after purchasing an additional 11,792 shares during the period. Cerity Partners LLC bought a new position in shares of Ventyx Biosciences in the first quarter worth approximately $56,000. Finally, Jane Street Group LLC bought a new position in shares of Ventyx Biosciences during the first quarter worth $56,000. Institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.